2-{4-[4-Nitro-3-({1-[(3s,5s,7s)-tricyclo[3.3.1.1~3,7~]dec-1-yl]ethyl}amino)phenyl]piperazin-1-yl}ethanol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-{4-[4-Nitro-3-({1-[(3s,5s,7s)-tricyclo[3.3.1.1~3,7~]dec-1-yl]ethyl}amino)phenyl]piperazin-1-yl}ethanol
• 英文别名: 2-[4-[3-[1-(1-adamantyl)ethylamino]-4-nitrophenyl]piperazin-1-yl]ethanol
• 化学式: C24H36N4O3
• 分子量: 428.6
• InChiKey: UFWACGHASKRRJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  84.6
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1902733A1

  公开（公告）日：2008-03-26

  The present invention relates to an active substance combination comprising at least one compound with 5-HT6 receptor affinity, and at least NMDA-receptor ligand, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament.

  本发明涉及一种由至少一种具有 5-HT6 受体亲和力的化合物和至少一种 NMDA 受体配体组成的活性物质组合、一种包含所述活性物质组合的药物，以及使用所述活性物质组合制造药物。
• NITRO-SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1851210B1

  公开（公告）日：2011-10-19
• COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2040755A1

  公开（公告）日：2009-04-01
• COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY
  申请人：Laboratorios Del. Dr. Esteve, S.A.

  公开号：EP2081600A1

  公开（公告）日：2009-07-29
• Nitro-Substituted Phenyl-Piperazine Compounds, Their Preparation and Use in Medicaments
  申请人：Aschenbrenner Andrea

  公开号：US20080176854A1

  公开（公告）日：2008-07-24

  The present invention relates to nitro-substituted phenyl-piperazine compounds of general formula I, a process for their preparation, medicaments comprising said nitro-substituted phenyl-piperazine compounds as well as the use of said nitro-substituted phenylpiperazine compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT 6 receptors.